General References

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

O
O’Donnell HC, Rosand J, Knudsen KA et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. New Eng J Med 2000; 342:240-5.

O’Riordan S, McMonagle P, Janssen JC et al. Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities. Neurology 2002; 59:1108-10.

Oakman C, Moretti E, Galardi F, Santarpia L, di Leo A. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. Cancer Treat Rev 2009; 35:662-7.

Oaxaca-Castillo D, Andreoletti P, Vluggens A et al. Biochemical characterization of two functional human liver acyl-CoA oxidase isoforms 1a and 1b encoded by a single gene. Biochem Biophys Res Commun 2007; 360:314-9.

Obach RS. Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. Drug Metab Dispos 2000; 28:1069-76.

Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John’s Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000; 294:88-95.

Obach RS. Cytochrome P450-catalyzed metabolism of ezlopitant alkene (CJ-12,458), a pharmacologically active metabolite of ezlopitant: enzyme kinetics and mechanism of an alkene hydration reaction. Drug Metab Dispos 2001; 29:1057-67.

Obach RS. Mechanism of cytochrome P4503A4- and 2D6-catalyzed dehydrogenation of ezlopitant as probed with isotope effects using five deuterated analogs. Drug Metab Dispos 2001; 29:1599-607.

Obach RS. Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances. Curr Opin Drug Discov Devel 2009; 12:81-9.

Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 2005; 33:262-70.

Obach RS, Margolis JM, Logman MJ. In vitro metabolism of CP-122,721 ((2S,3S)-2-phenyl-3-[(5-trifluoromethoxy-2-methoxy)benzylamino]piperidine), a non-peptide antagonist of the substance P receptor. Drug Metab Pharmacokinet 2007; 22:336-49.

Obach RS, Reed-Hagen AE. Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos 2002; 30:831-7.

Obach RS, Ryder TF. Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos 2010; 38:1381-91.

Obach RS, Zhang QY, Dunbar D, Kaminsky LS. Metabolic characterization of the major human small intestinal cytochrome p450s. Drug Metab Dispos 2001; 29:347-52.

O’Barr SA, Oh JS, Ma C, Brent GA, Schultz JJ. Thyroid hormone regulates endogenous amyloid-beta precursor protein gene expression and processing in both in vitro and in vivo models. Thyroid 2006; 16:1207-13.

Ober C, Xiang KS, Thisted RA, Indovina KA, Wason CJ, Dooley S. Increased risk for gestational diabetes mellitus associated with insulin receptor and insulin-like growth factor II restriction fragment length polymorphisms. Genet Epidemiol 1989; 6:559-69.

Obermeier M, Yao M, Khanna A et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos 2010; 38:405-14.

Obici L, Bellotti V, Mangione P et al. The new apolipoprotein A-I variant leu174-to-ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide. Am J Pathol 1999; 155:695-702.

O’Brien C, Cavet G, Pandita A et al. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res 2008; 68:5380-9.

O’Brien DP, Gale KM, Anderson JS et al. Purification and characterization of factor VII 304-Gln: a variant molecule with reduced activity isolated from a clinically unaffected male. Blood 1991; 78:132-40.

O’Brien MM, Lacayo NJ, Lum BL et al. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2010; 54:694-702.

O’Brien SG, Meinhardt P, Bond E et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 2003; 89:1855-9.

O’Brien TR, McDermott DH, Ioannidis JP et al. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS 2000; 14:821-6.

O’Brien WT, Klein PS. Validating GSK3 as an in vivo target of lithium action. Biochem Soc Trans 2009; 37:1133-8.

O’Bryant CL, Lieu CH, Leong S et al. A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state. Cancer Chemother Pharmacol 2009; 63:477-89.

Obulesu M, Dowlathabad MR, Bramhachari PV. Carotenoids and Alzheimer’s Disease: An insight into therapeutic role of retinoids in animal models. Neurochem Int 2011; 59:535-41.

Ociepa-Zawal M, Rubiś B, Filas V, Breborowicz J, Trzeciak WH. Studies on CYP1A1, CYP1B1 and CYP3A4 gene polymorphisms in breast cancer patients. Ginekol Pol 2009; 80:819-23.

O’Connell MB, Frye RF, Matzke GR et al. Effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women. J Clin Pharmacol 2006; 46:1299-307.

O’Connor A, Phelan N, Tun TK, Boran G, Gibney J, Roche HM. High-molecular-weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance. J Clin Endocrinol Metab 2010; 95:1378-85.

O’Connor FF, Shields DC, Fitzgerald A et al. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood 2001; 98:3256-60.

O’Connor JE, Martínez A, Castell JV, Gómez-Lechón MJ. Multiparametric characterization by flow cytometry of flow-sorted subpopulations of a human hepatoma cell line useful for drug research. Cytometry A 2005; 63:48-58.

Ocraft KP, Muskett JM, Brown S. Localization of the human arylhydrocarbon hydroxylase gene to the 2q31-2pter region of chromosome 2. Ann Hum Genet 1985; 49:237-9.

Ochi R, Gupte SA. Ryanodine receptor: a novel therapeutic target in heart disease. Recent Patents Cardiovasc Drug Discov 2007; 2:110-8.

Ochi S, Kawasoe K, Abe M et al. A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation. Gen Hosp Psychiatry 2011. doi:10. 1016/j. genhosppsych. 2011. 03. 003.

Ochiai Y, Katsu H, Okino S, Wakutsu N, Nakayama K. Case of prolonged recovery from serotonin syndrome caused by paroxetine. Seishin Shinkeigaku Zasshi 2003; 105:1532-8.

Oda K, Yamaguchi Y, Yoshimura T, Wada K, Nishizono N. Synthetic models related to furanocoumarin-CYP 3A4 interactions. comparison of furanocoumarin, coumarin, and benzofuran dimers as potent inhibitors of CYP3A4 activity. Chem Pharm Bull 2007; 55:1419-21.

Oda M, Kotegawa T, Tsutsumi K, Ohtani Y, Kuwatani K, Nakano S. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. Eur J Clin Pharmacol 2003; 59:615-9.

Oda Y, Furuichi K, Tanaka K et al. Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450. Anesthesiology 1995; 82:214-20.

Oda Y, Hirayama T, Watanabe T. Genotoxic activation of the environmental pollutant 3,6-dinitrobenzo[e]pyrene in Salmonella typhimurium umu strains expressing human cytochrome P450 and N-acetyltransferase. Toxicol Lett 2009; 188:258-62.

Oda Y, Kharasch ED. Metabolism of levo-alpha-Acetylmethadol (LAAM) by human liver cytochrome P450: involvement of CYP3A4 characterized by atypical kinetics with two binding sites. J Pharmacol Exp Ther 2001; 297:410-22.

Oda Y, Kharasch ED. Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther 2001; 298:1021-32.

Oda Y, Mizutani K, Hase I, Nakamoto T, Hamaoka N, Asada A. Fentanyl inhibits metabolism of midazolam: competitive inhibition of CYP3A4 in vitro. Br J Anaesth 1999; 82:900-3.

Oda Y, Watanabe T, Terao Y, Nukaya H, Wakabayashi K. Genotoxic activation of 2-phenylbenzotriazole-type compounds by human cytochrome P4501A1 and N-acetyltransferase expressed in Salmonella typhimurium umu strains. Mutat Res 2008; 654:52-7.

Odani A, Hashimoto Y, Otsuki Y et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther 1997; 62:287-92.

Oddo S, Caccamo A, Shepherd JD et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39:409-21.

Odin E, Wettergren Y, Nilsson S et al. Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients. Clin Cancer Res 2003; 9:6012-9.

Odley A, Hahn HS, Lynch RA et al. Regulation of cardiac contractility by Rab4-modulated beta-2-adrenergic receptor recycling. Proc Nat Acad Sci USA 2004; 101:7082-7.

O’Donnell CJ, Grime K, Courtney P, Slee D, Riley RJ. The development of a cocktail CYP2B6, CYP2C8, and CYP3A5 inhibition assay and a preliminary assessment of utility in a drug discovery setting. Drug Metab Dispos 2007; 35:381-5.

O’Donnell CJ, Lindpaintner K, Larson MG et al. Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation 1998; 97:1766-72.

O’Donnell CP, Tankersley CG, Polotsky VP, Schwartz AR, Smith PL. Leptin, obesity, and respiratory function. Respir Physiol 2000; 119:163-70.

O’Donnell EF, Saili KS, Koch DC et al. The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor. PLoS One 2010. doi:10. 1371/journal. pone. 0013128

Oechsler S, Skopp G. An in vitro approach to estimate putative inhibition of buprenorphine and norbuprenorphine glucuronidation. Int J Legal Med 2010; 124:187-94.

Oelkers P, Kirby LC, Heubi JE, Dawson PA. Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). J Clin Invest 1997; 99:1880-7.

Oertel B, Lötsch J. Genetic mutations that prevent pain: implications for future pain medication. Pharmacogenomics 2008; 9:179-94.

Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lotsch J. The mu-opioid receptor gene polymorphism 118A-G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenetics Genomics 2006; 16:625-636.

Oesterheld JR. A review of developmental aspects of cytochrome P450. J Child Adolesc Psychopharmacol 1998; 8:161-74.

Oesterheld JR, Armstrong SC, Cozza KL. Ecstasy: pharmacodynamic and pharmacokinetic interactions. Psychosomatics 2004; 45:84-7.

Oeveren van-Dybicz AM, Vonkeman HE, Bon MA, van den Bergh FA, Vermes I. Beta 3-adrenergic receptor gene polymorphism and type 2 diabetes in a Caucasian population. Diabetes Obes Metab 2001; 3:47-51.

Offman EM, Freeman DJ, Dresser GK, Munoz C, Bend JR, Bailey DG. Red wine-cisapride interaction: comparison with grapefruit juice. Clin Pharmacol Ther 2001; 70:17-23.

Oganesian A, Shilling AD, Young-Sciame R et al. Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome p450 and p-glycoprotein activities. Psychopharmacol Bull 2009; 42:47-63.

Ogasawara A, Kume T, Kazama E. Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys. Drug Metab Dispos 2007; 35:410-8.

Ogata M. Acatalasemia. Hum Genet 1991; 86:331-40.

Ogata M, Wang DH, Ogino K. Mammalian acatalasemia: the perspectives of bioinformatics and genetic toxicology. Acta Med Okayama 2008; 62:345-61.

Ogawa H, Nakamura R, Baba K. Source beneficial effect of laserpitin, a coumarin compound from Angelica keiskei, on lipid metabolism in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2005; 32:1104-9.

Ogawa S, Emi M, Shiraki M, Hosoi T, Ouchi Y, Inoue S. Association of estrogen receptor beta (ESR2) gene polymorphism with blood pressure. J Hum Genet 2000; 45:327-30.

Ogawa S, Hirano N, Sato N et al. Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. Blood 1994; 84:2431-5.

Ogawa S, Urano T, Hosoi T et al. Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts. Biochem Biophys Res Commun 1999; 260:122-6.

Ogburn ET, Jones DR, Masters AR, Xu C, Guo Y, Desta Z. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos 2010; 38:1218-29.

Ogg MS, Gray TJ, Gibson GG. Development of an in vitro reporter gene assay to assess xenobiotic induction of the human CYP3A4 gene. Eur J Drug Metab Pharmacokinet 1997; 22:311-3.

Ogg MS, Williams JM, Tarbit M, Goldfarb PS, Gray TJ, Gibson GG. A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro. Xenobiotica 1999; 29:269-79.

Ogilvie BW, Yerino P, Kazmi F et al. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos 2011; 39:2020-33.

Ogino M, Nagata K, Yamazoe Y. Selective suppressions of human CYP3A forms, CYP3A5 and CYP3A7, by troglitazone in HepG2 cells. Drug Metab Pharmacokinet 2002; 17:42-6.

Ogle RF, Christodoulou J, Fagan E et al. Mitochondrial myopathy with tRNA(Leu(UUR)) mutation and complex I deficiency responsive to riboflavin. J Pediatr 1997; 130:138-45.

Ognjanovic S, Yamamoto J, Saltzman B et al. Serum CRP and IL-6, genetic variants and risk of colorectal adenoma in a multiethnic population. Cancer Causes Control 2010; 21:1131-8.

Oh EY, Min KM, Chung JH et al. Significance of Pro12Ala mutation in peroxisome proliferator-activated receptor-gamma2 in Korean diabetic and obese subjects. J Clin Endocrinol Metab 2000; 85:1801-4.

Oh HT, Chung MJ, Kim SH, Choi HJ, Ham SS. Masou salmon (Oncorhynchus masou) ethanol extract decreases 3-hydroxy-3-methylglutaryl coenzyme A reductase expression in diet-induced obese mice. Nutr Res 2009; 29:123-9.

Oh IH, Oh C, Kim HJ et al. Genetic associations of IL1RN polymorphisms with metabolic syndrome in a Korean population. Exp Clin Endocrinol Diabetes 2010; 118:333-7.

Oh JH, Dong MS, Choi MG et al. Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin. J Gastroenterol Hepatol 2009; 24:294-8.

Oh KY, Kang MJ, Choi WA et al. Association Between Serum IgE Levels and the CTLA4 +49A/G and FCER1B -654C/T Polymorphisms in Korean Children With Asthma. Allergy Asthma Immunol Res 2010; 2:127-33.

Oh WK, Cho KB, Hien TT et al. Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1. Mol Pharmacol 2010; 78:855-64.

Oh WS, Kim DN, Jung J, Cho KH, No KT. New combined model for the prediction of regioselectivity in cytochrome P450/3A4 mediated metabolism. J Chem Inf Model 2008; 48:591-601.

Oh YH, Han HK. Altered pharmacokinetics of zalcitabine by concurrent use of NSAIDs in rats. Acta Pharmacol Sin 2006; 27:119-22.

O’Hara GE, Philippon F, Gilbert M et al. Combined administration of quinidine and propafenone for atrial fibrillation: The CAQ-PAF study. J Clin Pharmacol 2011. doi:10. 1177/0091270011399574.

Ohara K, Nagai M, Ohara K. Apolipoprotein E epsilon 4 and clinical phenotype in schizophrenia. Lancet 1997; 350:1857.

Ohara K, Tanabu S, Ishibashi K, Ikemoto K, Yoshida K, Shibuya H. CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects. Eur J Clin Pharmacol 2003; 58:659-61.

Ohara K, Tanabu S, Ishibashi K, Ikemoto K, Yoshida K, Shibuya H. Effects of age and the CYP2D6*10 allele on the plasma haloperidol concentration/dose ratio. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:347-50.

Ohara K, Tanabu S, Yoshida K, Ishibashi K, Ikemoto K, Shibuya H. Effects of smoking and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration/dose ratio. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:945-9.

Ohe T, Hirobe M, Mashino T. Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos 2000; 28:110-2.

Ohhira S, Enomoto M, Matsui H. In vitro metabolism of tributyltin and triphenyltin by human cytochrome P-450 isoforms. Toxicology 2006; 228:171-7.

Ohiwa M, Hayashi T, Wada H, Minamikawa K, Shirakawa S, Suzuki K. Factor VII Mie: homozygous asymptomatic type I deficiency caused by an amino acid substitution of His (CAC) for Arg(247) (CGC) in the catalytic domain. Thromb Haemost 1994; 71:773-7.

Ohkubo K, Nagashima M, Naito Y et al. Genotypes of the pancreatic beta-cell K-ATP channel and clinical phenotypes of Japanese patients with persistent hyperinsulinaemic hypoglycaemia of infancy. Clin Endocrinol 2005; 62:458-65.

Ohkubo T, Sakasegawa Y, Asada T et al. Absence of association between codon 129/219 polymorphisms of the prion protein gene Alzheimer’s disease in Japan. Ann Neurol 2003; 54:553-4.

Ohkura K, Kawaguchi Y, Watanabe Y, Masubuchi Y, Shinohara Y, Hori H. Flexible structure of cytochrome P450: promiscuity of ligand binding in the CYP3A4 heme pocket. Anticancer Res 2009; 29:935-42.

Ohlin AK, Marlar RA. The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease. Blood 1995; 85:330-6.

Ohmann EL, Burckart GJ, Brooks MM et al. Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients. J Heart Lung Transplant 2010; 29:509-16.

Ohmichi N, Iwai N, Uchida Y, Shichiri G, Nakamura Y, Kinoshita M. Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. Am J Hypertens 1997; 10:951-5.

Ohmori O, Shinkai T, Hori H, Nakamura J. Novel polymorphism in the 5’-upstream region of the human 5-HT6 receptor gene and schizophrenia. Neurosci Lett 2001; 310:17-20.

Ohmori S, Nakasa H, Asanome K et al. Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochim Biophys Acta 1998; 1380:297-304.

Ohnishi A, Emi Y. Rapid proteasomal degradation of translocation-deficient UDP-glucuronosyltransferase 1A1 proteins in patients with Crigler-Najjar type II. Biochem Biophys Res Commun 2003; 310:735-41.

Ohnishi A, Matsuo H, Yamada S et al. Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4. Br J Pharmacol 2000; 130:1369-77.

Ohnmacht S, Nava P, West R, Parker R, Atkinson J. Inhibition of oxidative metabolism of tocopherols with omega-N-heterocyclic derivatives of vitamin E. Bioorg Med Chem 2008; 16:7631-8.

Ohno K, Tsujino A, Brengman JM et al. Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans. Proc Natl Acad Sci USA 2001; 98:2017-22.

Ohno M, Darwish WS, Ikenaka Y, Miki W, Ishizuka M. Astaxanthin can alter CYP1A-dependent activities via two different mechanisms: induction of protein expression and inhibition of NADPH P450 reductase dependent electron transfer. Food Chem Toxicol 2011; 49:1285-91.

Ohno M, Motojima K, Okano T, Taniguchi A. Induction of drug-metabolizing enzymes by phenobarbital in layered co-culture of a human liver cell line and endothelial cells. Biol Pharm Bull 2009; 32:813-7.

Ohno T, Nakade S, Nakayama K et al. Absolute bioavailability of imidafenacin after oral administration to healthy subjects. Br J Clin Pharmacol 2008; 65:197-202.

Ohno T, Nakayama K, Nakade S et al. Effect of itraconazole on the pharmacokinetics of imidafenacin in healthy subjects. J Clin Pharmacol 2008; 48:330-4.

Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet 2007; 46:681-96.

Ohno Y, Hisaka A, Ueno M, Suzuki H. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin Pharmacokinet 2008; 47:669-80.

Ohnsorg PM, Rohrer L, Perisa D et al. Carboxyl terminus of apolipoprotein A-I (ApoA-I) is necessary for the transport of lipid-free ApoA-I but not prelipidated ApoA-I particles through aortic endothelial cells. J Biol Chem 2011; 286:7744-54.

Ohnuma S, Chufán EE, Nandigama K et al. Inhibition of multidrug resistance-linked P-glycoprotein (ABCB1) function by 5’-Fluorosulfonylbenzoyl 5’-Adenosine: Evidence for an ATP analog that interacts with both drug-substrate-and nucleotide-binding sites. Biochemistry 2011; 50:3724-35.

Ohnuma T, Anan E, Hoashi R et al. Dietary diacetylene falcarindiol induces phase 2 drug-metabolizing enzymes and blocks carbon tetrachloride-induced hepatotoxicity in mice through suppression of lipid peroxidation. Biol Pharm Bull 2011; 34:371-8.

Ohnuma T, Shibata N, Matsubara Y, Arai H. Haloperidol plasma concentration in Japanese psychiatric subjects with gene duplication of CYP2D6. Br J Clin Pharmacol 2003; 56:315-20.

Ohsako S, Deguchi T. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. J Biol Chem 1990; 265:4630-4.

Ohsawa I, Nishimaki K, Murakami Y, Suzuki Y, Ishikawa M, Ohta S. Age-dependent neurodegeneration accompanying memory loss in transgenic mice defective in mitochondrial aldehyde dehydrogenase 2 activity. J Neurosci 2008; 28:6239-49.

Ohshige T, Tanaka Y, Araki S et al. A single nucleotide polymorphism in KCNQ1 is associated with susceptibility to diabetic nephropathy in japanese subjects with type 2 diabetes. Diabetes Care 2010; 33:842-6.

Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001; 414:916-20.

Ohta T, Nagahashi M, Hosoi S, Tsukamoto S. Dihydroxybergamottin caproate as a potent and stable CYP3A4 inhibitor. Bioorg Med Chem 2002; 10:969-73.

Ohta T, Okamoto K, Isohashi F et al. T-loop deletion of CDC2 from breast cancer tissues eliminates binding to cyclin B1 and cyclin-dependent kinase inhibitor p21. Cancer Res 1998; 58:1095-8.

Ohtake F, Baba A, Takada I et al. Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature 2007; 446:562-6.

Ohtsuka K, Ohnishi H, Morii T et al. Downregulated ABCG2 enhances sensitivity to topoisomerase I inhibitor in epidermal growth factor receptor tyrosine kinase inhibitor-resistant non-small cell lung cancer. J Thorac Oncol 2010; 5:1726-33.

Ohtsuki S, Kamoi M, Watanabe Y, Suzuki H, Hori S, Terasaki T. Correlation of induction of ATP binding cassette transporter A5 (ABCA5) and ABCB1 mRNAs with differentiation state of human colon tumor. Biol Pharm Bull 2007; 30:1144-6.

Ohtsuki T, Tsuda H, Morimoto C. Good or evil: CD26 and HIV infection. J Dermatol Sci 2000; 22:152-60.

Ohura T, Morita M, Kuruto-Niwa R, Amagai T, Sakakibara H, Shimoi K. Differential action of chlorinated polycyclic aromatic hydrocarbons on aryl hydrocarbon receptor-mediated signaling in breast cancer cells. Environ Toxicol 2010; 25:180-7.

Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 2000; 28:1303-10.

Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol 2000; 49:244-53.

Ohyama Y, Yamasaki T. Eight cytochrome P450s catalyze vitamin D metabolism. Front Biosci 2004; 9:3007-18.

Oikawa S, Matsunaga A, Saito T et al. Apolipoprotein E Sendai (arginine 145-proline): a new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol 1997; 8:820-3.

Oinonen T, Ronis M, Wigell T, Tohmo K, Badger T, Lindros KO. Growth hormone-regulated periportal expression of CYP2C7 in rat liver. Biochem Pharmacol 2000; 59:583-9.

Oishi M, Chiba K, Malhotra B, Suwa T. Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics. Drug Metab Dispos 2010; 38:1456-63.

Oishi M, Chiba K, Malhotra B, Suwa T. Pharmacokinetics of tolterodine in Japanese and Koreans: physiological and stochastic assessment of ethnic differences. Drug Metab Pharmacokinet 2011; 26:236-41.

Ojanperä S, Rasanen I, Sistonen J, Pelander A, Vuori E, Ojanperä I. Quantification of drugs in plasma without primary reference standards by liquid chromatography-chemiluminescence nitrogen detection: application to tramadol metabolite ratios. Ther Drug Monit 2007; 29:423-8.

Okada T, Sato-Furuhashi N, Iwata F, Mugishima H. The interaction between intestinal fatty acid-binding protein 2 polymorphism and delta-6 desaturase activity in obese children. Am J Clin Nutr 2008; 87:1066-7.

Okada Y, Nakamura K, Hiromura K, Nojima Y, Horiuchi R, Yamamoto K. Pro32Thr polymorphism of inosine triphosphate pyrophosphatase gene predicts efficacy of low-dose azathioprine for patients with systemic lupus erythematosus. Clin Pharmacol Ther 2009; 85:527-30.

Okamura N, Suemoto T, Shimadzu H et al. Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J Neurosci 2004; 24:2535-41.

Okamura T, Ishii Y, Suzuki Y et al. Enhancing effects of carbon tetrachloride on in vivo mutagenicity in the liver of mice fed 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx). J Toxicol Sci 2010; 35:709-20.

Okegawa T, Nutahara K, Higashihara E. Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer. Int J Urol 2010; 17:466-75.

Okey AB. An aryl hydrocarbon receptor odyssey to the shores of toxicology: the Deichmann Lecture, International Congress of Toxicology-XI. Toxicol Sci 2007; 98:5-38.

Oki K, Yamane K, Satoh K, Nakanishi S, Yamamoto H, Kohno N. Aldosterone synthase (CYP11B2) C-344T polymorphism affects the association of age-related changes of the serum C-reactive protein. Hypertens Res 2010; 33:326-30.

Okishiro M, Taguchi T, Jin Kim S, Shimazu K, Tamaki Y, Noguchi S. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer 2009; 115:952-61.

Okochi M, Steiner H, Fukimori A et al. Presenilins mediate a dual intramembranous gamma-secretase clavage of Notch-1. EMBO J 2002; 21:5408-16.

Okpechi IG, Rayner BL, van der Merwe L et al. Genetic variation at selected SNPs in the leptin gene and association of alleles with markers of kidney disease in a Xhosa population of South Africa. PLoS One 2010. doi:10. 1371/journal. pone. 0009086.

Oksenberg JR, Barcellos LF, Cree BA et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 2004; 74:160-7.

Okubo K, Takeuchi A, Chaube R et al. Sex differences in aromatase gene expression in the medaka brain. J Neuroendocrinol 2011; 23:412-23.

Okubo S, Niimura F, Nishimura H et al. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest 1997; 99:855-60.

Okuhira K, Fitzgerald ML, Tamehiro N et al. Binding of PDZ-RhoGEF to ATP-binding cassette transporter A1 (ABCA1) induces cholesterol efflux through RhoA activation and prevention of transporter degradation. J Biol Chem 2010; 285:16369-77.

Okuma K, Tanaka R, Ogura T et al. Interleukin-4-transgenic hu-PBL-SCID mice: a model for the screening of antiviral drugs and immunotherapeutic agents against X4 HIV-1 viruses. J Infect Dis 2008; 197:134-41.

Okumura K, Kita T, Chikazawa S, Komada F, Iwakawa S, Tanigawara Y. Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism. Clin Pharmacol Ther 1997; 61:509-17.

Okumus G, Kiyan E, Arseven O et al. Platelet glycoprotein Ia 807C/T and 873G/A polymorphisms in patients with venous thromboembolism. Clin Appl Thromb Hemost 2007; 13:101-3.

Okura T, Ibe M, Umegaki K, Shinozuka K, Yamada S. Effects of dietary ingredients on function and expression of P-glycoprotein in human intestinal epithelial cells. Biol Pharm Bull 2010; 33:255-9.

Okuyama Y, Hazama S, Nozawa H et al. Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1*28/*6 polymorphisms. Jpn J Clin Oncol 2011; 41:477-82.

Oldenburg J, Bevans CG, Fregin A et al. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 2007; 98:570-8.

Oldenburg J, Kraggerud SM, Brydøy M, Cvancarova M, Lothe RA, Fossa SD. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med 2007; 5:70.

Oldham HG, Clarke SE. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab Dispos 1997; 25:970-7.

Oleksiak MF, Wu S, Parker C et al. Identification and regulation of a new vertebrate cytochrome P450 subfamily, the CYP2Ps, and functional characterization of CYP2P3, a conserved arachidonic acid epoxygenase/19-hydroxylase. Arch Biochem Biophys 2003; 411:223-34.

Olesen OV, Linnet K. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos 1997; 25:740-4.

Olesen OV, Linnet K. Studies on the stereoselective metabolism of citalopram by human liver microsomas and cDNA-expressed cytochrome P450 enzymes. Pharmacology 1999; 59:298-309.

Olesen OV, Linnet K. Fluvoxamine-Clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. J Clin Psychopharmacol 2000; 20:35-42.

Olesen OV, Linnet K. Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol 2000; 50:563-71.

Olesen OV, Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 2001; 41:823-32.

Olichney JM, Hansen LA, Galasko D et al. The apolipoprotein E epsilon-4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer’s disease and Lewy body variant. Neurology 1996; 47:190-6.

Olié JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007; 10:661-73.

Olinga P, Elferink MG, Draaisma AL et al. Coordinated induction of drug transporters and phase I and II metabolism in human liver slices. Eur J Pharm Sci 2008; 33:380-9.

Oliva A, Hu D, Viskin S et al. SCN5A mutation associated with acute myocardial infarction. Leg Med 2009; 11 Suppl 1:206-9.

Oliva J, Bardag-Gorce F, Tillman B, French SW. Protective effect of quercetin, EGCG, catechin and betaine against oxidative stress induced by ethanol in vitro. Exp Mol Pathol 2011; 90:295-9.

Oliva R, Pastor P. Tau gene delN296 mutation, Parkinson’s disease, and atypical supranuclear palsy. Ann Neurol 2004; 55:448-9.

Oliveira E, Marsh S, van Booven DJ, Amorim A, Prata MJ, McLeod HL. Pharmacogenetically relevant polymorphisms in Portugal. Pharmacogenomics 2007; 8:703-12.

Oliveira E, Pereira R, Amorim A, McLeod H, Prata MJ. Patterns of pharmacogenetic diversity in African populations: role of ancient and recent history. Pharmacogenomics 2009; 10:1413-22.

Oliver P, Lubomirov R, Carcas A. Genetic polymorphisms of CYP1A2, CYP3A4, CYP3A5, pregnane/steroid X receptor and constitutive androstane receptor in 207 healthy Spanish volunteers. Clin Chem Lab Med 2010; 48:635-9.

Olivieri EH, da Silva SD, Mendonça FF et al. CYP1A2*1C, CYP2E1*5B, and GSTM1 polymorphisms are predictors of risk and poor outcome in head and neck squamous cell carcinoma patients. Oral Oncol 2009; 45:73-9.

Olivieri O, Stranieri C, Girelli D et al. Homozygosity for angiotensinogen 235T variant increases the risk of myocardial infarction in patients with multi-vessel coronary artery disease. J Hypertens 2001; 19:879-84.

Olivo-Marston SE, Hursting SD, Lavigne J et al. Genetic reduction of circulating insulin-like growth factor-1 inhibits azoxymethane-induced colon tumorigenesis in mice. Mol Carcinog 2009; 48:1071-6.

Olkkola KT, Ahonen J. Midazolam and other benzodiazepines. Handb Exp Pharmacol 2008; 335-60.

Olkkola KT, Isohanni MH, Hamunen K, Neuvonen PJ. The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. Anesth Analg 2005; 100:1352-6.

Olmos C, Sandoval R, Rozas C et al. Effect of short-term exposure to dichlorvos on synaptic plasticity of rat hippocampal slices: involvement of acylpeptide hydrolase and alpha(7) nicotinic receptors. Toxicol Appl Pharmacol 2009; 238:37-46.

Olmos Y, Valle I, Borniquel S et al. Mutual dependence of Foxo3a and PGC-1alpha in the induction of oxidative stress genes. J Biol Chem 2009; 284:14476-84.

Olsen AK, Hansen KT, Friis C. Pig hepatocytes as an in vitro model to study the regulation of human CYP3A4: prediction of drug-drug interactions with 17 alpha-ethynylestradiol. Chem Biol Interact 1997; 107:93-108.

Olshan AF, Weissler MC, Watson MA, Bell DA. Risk of head and neck cancer and the alcohol dehydrogenase 3 genotype. Carcinogenesis 2001; 22:57-61.

Olson CR, Mello CV. Significance of vitamin A to brain function, behavior and learning. Mol Nutr Food Res 2010; 54:489-95.

Olson LE, Soriano P. Increased PDGFRalpha activation disrupts connective tissue development and drives systemic fibrosis. Dev Cell 2009; 16:303-13.

Olsson M, Ekström L, Guillemette C, Belanger A, Rane A, Gustafsson O. Correlation between circulatory, local prostatic, and intra-prostatic androgen levels. Prostate 2011; 71:909-14.

Olubodun JO, Ochs HR, von Moltke LL et al. Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. Br J Clin Pharmacol 2003; 56:297-304.

Olver I, Shelukar S, Thompson KC. Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant. Int J Nanomedicine 2007; 2:13-8.

Olvera-Bello AE, Estrada-Muñiz E, Elizondo G, Vega L. Susceptibility to the cytogenetic effects of dichloromethane is related to the glutathione S-transferase theta phenotype. Toxicol Lett 2010; 199:218-24.

Olyaei AJ, deMattos AM, Norman DJ, Bennett WM. Interaction between tacrolimus and nefazodone in a stable renal transplant recipient. Pharmacotherapy 1998; 18:1356-9.

Omalu B, Bailes J, Hamilton RL et al. Emerging histomorphologic phenotypes of chronic traumatic encephalopathy [CTE] in American athletes. Neurosurgery 2011; 69:173-183.

Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35:1096-107.

Omasa T, Kim K, Hiramatsu S et al. Construction and evaluation of drug-metabolizing cell line for bioartificial liver support system. Biotechnol Prog 2005; 21:161-7.

O’Mathúna B, Farré M, Rostami-Hodjegan A et al. The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. J Clin Psychopharmacol 2008; 28:523-9.

Omkvist DH, Brodin B, Nielsen CU. Ibuprofen is a non-competitive inhibitor of the peptide transporter hPEPT1 (SLC15A1): possible interactions between hPEPT1 substrates and ibuprofen. Br J Pharmacol 2010; 161:1793-805.

Onaivi ES. Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications. Int Rev Neurobiol 2009; 88:335-69.

Onalan O, Cumurcu BE, Bekar L. Complete atrioventricular block associated with concomitant use of metoprolol and paroxetine. Mayo Clin Proc 2008; 83:595-9.

Oneda B, Crettol S, Sirot EJ, Bochud M, Ansermot N, Eap CB. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet Genomics 2009; 19:877-83.

Oner Ozgon G, Langaee TY, Feng H et al. VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients. Eur J Clin Pharmacol 2008; 64:889-94.

Ong-Ajyooth S, Ong-Ajyooth L, Limmongkon A, Tiensingh A, Parichatikanon P, Nilwarangkur S. The renin-angiotensin system gene polymorphisms and clinicopathological correlations in IgA nephropathy. J Med Assoc Thai 1999; 82:681-9.

Oniki K, Hori M, Takata K et al. Association between glutathione S-transferase A1, M1 and T1 polymorphisms and hypertension. Pharmacogenet Genomics 2008; 18:275-7.

Onitilo AA, McCarty CA, Wilke RA et al. Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res Treat 2009; 115:643-50.

Onizuka M, Kunii N, Toyosaki M et al. Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients. Bone Marrow Transplant 2011; 46:1113-7.

Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro. Exp Neurol 2004; 189:380-92.

Ono S, Hatanaka T, Miyazawa S et al. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica 1996; 26:1155-66.

Ono S, Mihara K, Suzuki A et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology 2002; 162:50-4.

Onyimba JA, Coronado MJ, Garton AE et al. The innate immune response to coxsackievirus B3 predicts progression to cardiovascular disease and heart failure in male mice. Biol Sex Differ 2011; 2:2.

Ooi JP, Kuroyanagi M, Sulaiman SF, Muhammad TS, Tan ML. Andrographolide and 14-deoxy-11, 12-didehydroandrographolide inhibit cytochrome P450s in HepG2 hepatoma cells. Life Sci 2011; 88:447-54.

Oomen JM, van Rossum CT, Hoebee B, Saris WH, van Baak MA. beta2-adrenergic receptor polymorphisms and salbutamol-stimulated energy expenditure. J Clin Endocrinol Metab 2005; 90:2301-7.

Oostendorp RL, Huitema A, Rosing H et al. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Clin Cancer Res 2009; 15:4228-33.

Oostendorp RL, Marchetti S, Beijnen JH, Mazzanti R, Schellens JH. The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate. Cancer Chemother Pharmacol 2007; 59:855-60.

Oota H, Dunn CW, Speed WC et al. Conservative evolution in duplicated genes of the primate Class I ADH cluster. Gene 2007; 392:64-76.

Ooyama A, Okayama Y, Takechi T, Sugimoto Y, Oka T, Fukushima M. Genome-wide screening of loci associated with drug resistance to 5-fluorouracil-based drugs. Cancer Sci 2007; 4:577-83.

Op den Buijsch RA, Christiaans MH, Stolk LM et al. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol 2007; 21:427-35.

Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 2000; 13:18-24.

Opdal SH, Opstad A, Vege A, Rognum TO. IL-10 gene polymorphisms are associated with infectious cause of sudden infant death. Hum Immunol 2003; 64:1183-9.

Opdal SH, Rognum TO, Torgersen H, Vege A. Mitochondrial DNA point mutations detected in four cases of sudden infant death syndrome. Acta Paediatr 1999; 88:957-60.

Oral EA, Simha V, Ruiz E et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002; 346:570-8.

Ordovás Baines JP, Climent Grana E, Jover Botella A, Valero García I. Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban. Farm Hosp 2009; 33:125-33.

Ordovas JM, Corella D, Demissie S et al. Dietary fat intake determines the effect of a common polymorphism in the hepatic lipase gene promoter on high-density lipoprotein metabolism: evidence of a strong dose effect in this gene-nutrient interaction in the Framingham Study. Circulation 2002; 106:2315-21.

Ordovas JM, Corella D. Nutritional genomics. Annu Rev Genomics Hum Genet 2004; 5:71-118.

Ordovas JM, Lopez-Miranda J, Perez-Jimenez F et al. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 1995; 113:157-66.

Ordovas JM, Schaefer EJ, Salem D et al. Apolipoprotein A-I gene polymorphism associated with premature coronary artery disease and familial hypoalphalipoproteinemia. New Eng J Med 1986; 314:671-7.

Ordway JM, Tallaksen-Greene S, Gutekunst CA et al. Ectopically expressed CAG repeats cause intracellular inclusions and progressive late onset neurological phenotype in the mouse. Cell 1997; 91:753-63.

Orio F Jr, Matarese G, Di Biase S et al. Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88:5887-92.

Orishiki M, Matsuo Y, Nishioka M, Ichikawa Y. In vivo administration of H2 blockers, cimetidine and ranitidine, reduced the contents of the cytochrome P450IID (CYP2D) subfamily and their activities in rat liver microsomes. Int J Biochem 1994; 26:751-8.

Orlando R, Piccoli P, de Martin S, Padrini R, Palatini P. Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol 2003; 55:86-93.

Orlicky DJ, Roede JR, Bales E et al. Chronic ethanol consumption in mice alters hepatocyte lipid droplet properties. Alcohol Clin Exp Res 2011; 35:1020-33.

Orlow I, Roy P, Reiner AS et al. Vitamin D receptor polymorphisms in patients with cutaneous melanoma. Int J Cancer 2011. doi:10. 1002/ijc. 26023.

Orolin J, Vecera R, Markova I, Zacharova A, Anzenbacher P. Differences in hepatic expression of genes involved in lipid homeostasis between hereditary hypertriglyceridemic rats and healthy Wistar rats and in their response to dietary cholesterol. Food Chem Toxicol 2009; 47:2624-30.

Orozco G, Barton A, Eyre S et al. HLA-DPB1-COL11A2 and three additional xMHC loci are independently associated with RA in a UK cohort. Genes Immun 2011; 12:169-75.

Orsi FA, Annichino Bizzacchi JM, de Paula EV, Ozelo MC, Langley MR, Weck KE. VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy. Thromb Res 2010; 126:206-10.

Orso E, Broccardo C, Kaminski WE et al. Transport of lipids from Golgi to plasma membrane is defective in Tangier disease patients and Abc1-deficient mice. Nat Genet 2000; 24:192-6.

Osada K, Suzuki T, Kawakami Y et al. Dose-dependent hypocholesterolemic actions of dietary apple polyphenol in rats fed cholesterol. Lipids 2006; 41:133-9.

Osada Y, Miyauchi R, Goda T et al. Variations in the WNK1 gene modulates the effect of dietary intake of sodium and potassium on blood pressure determination. J Hum Genet 2009; 54:474-8.

Osaka Y, Inomata S, Tanaka E et al. Effect of propofol on ropivacaine metabolism in human liver microsomes. J Anesth 2006; 20:60-3.

Osanai T, Ohkubo T, Yasui N, Kondo T, Kaneko S. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam. Br J Clin Pharmacol 2004; 58:476-81.

Osawa N, Koya D, Araki S et al. Combinational effect of genes for the renin-angiotensin system in conferring susceptibility to diabetic nephropathy. J Hum Genet 2007; 52:143-51.

Osbild S, Bour J, Maunit B et al. Interaction of the electrophilic ketoprofenyl-glucuronide and ketoprofenyl-coenzyme A conjugates with cytosolic glutathione S-transferases. Drug Metab Dispos 2008; 36:260-7.

Oscarson M, Gullstén H, Rautio A et al. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett 1998; 438:201-5.

Oscarson M, Hidestrand M, Johansson I, Ingelman-Sundberg M. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol 1997; 52:1034-40.

Oscarson M, McLellan RA, Asp V et al. Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum Mutat 2002; 20:275-83.

Oscarson M, McLellan RA, Gullstén H et al. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett 1999; 448:105-10.

Oscarson M, McLellan RA, Gullstén H et al. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett 1999; 460:321-7.

Oscarson M, Zanger UM, Rifki OF, Klein K, Eichelbaum M, Meyer UA. Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther 2006; 80:440-56.

Ose A, Ito M, Kusuhara H et al. Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos 2009; 37:315-21.

Oselin K, Gerloff T, Mrozikiewicz PM, Pähkla R, Roots I. MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam Clin Pharmacol 2003; 17:463-9.

O’Shaughnessy PJ, Monteiro A, Bhattacharya S, Fowler PA. Maternal smoking and fetal sex significantly affect metabolic enzyme expression in the human fetal liver. J Clin Endocrinol Metab 2011; 96:2851-60.

Osier M, Pakstis AJ, Kidd JR et al. Linkage disequilibrium at the ADH2 and ADH3 loci and risk of alcoholism. Am J Hum Genet 1999; 64:1147-57.

Osier MV, Pakstis AJ, Soodyall H et al. A global perspective on genetic variation at the ADH genes reveals unusual patterns of linkage disequilibrium and diversity. Am J Hum Genet 2002; 71:84-99.

Oslin DW, Berrettini W, Kranzler HR et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003; 28:1546-52.

Osna NA, White RL, Donohue TM Jr, Beard MR, Tuma DJ, Kharbanda KK. Impaired methylation as a novel mechanism for proteasome suppression in liver cells. Biochem Biophys Res Commun 2010; 391:1291-6.

Osswald E, Johne A, Laschinski G et al. Association of MDR1 genotypes with susceptibility to colorectal cancer in older non-smokers. Eur J Clin Pharmacol 2007; 63:9-16.

Ostberg T, Bertilsson G, Jendeberg L, Berkenstam A, Uppenberg J. Identification of residues in the PXR ligand binding domain critical for species specific and constitutive activation. Eur J Biochem 2002; 269:4896-904.

Ostergaard JR, Sunde L, Okkels H. Neurofibromatosis von Recklinghausen type I phenotype and early onset of cancers in siblings compound heterozygous for mutations in MSH6. Am J Med Genet A 2005; 139:96-105.

Osterreicher CH, Taura K, de Minicis S et al. Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. Hepatology 2009; 50:929-38.

Ostuni A, Miglionico R, Castiglione Morelli MA, Bisaccia F. Study of the nucleotide-binding domain 1 of the human transporter protein MRP6. Protein Pept Lett 2010; 17:1553-8.

Osuntokun BO, Sahota A, Ogunniyi AO et al. Lack of an association between apolipoprotein E epsilon-4 and Alzheimer’s disease inelderly Nigerians. Ann Neurol 1995; 38:463-5.

Oswald S, Giessmann T, Luetjohann D et al. Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clin Pharmacol Ther 2006; 80:477-85.

Oswald S, Haenisch S, Fricke C et al. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther 2006; 79:206-17.

Oswald S, König J, Lütjohann D et al. Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1. Pharmacogenet Genomics 2008; 18:559-68.

Oswald S, May K, Rosin J, Lütjohann D, Siegmund W. Synergistic influence of Abcb1 and Abcc2 on disposition and sterol lowering effects of ezetimibe in rats. J Pharm Sci 2010; 99:422-9.

Oswald S, Nassif A, Modess C et al. Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clin Pharmacol Ther 2010; 87:663-7.

Oswald S, Nassif A, Modess C et al. Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther 2011; 89:524-8.

Oswald S, Terhaag B, Siegmund W. In vivo probes of drug transport: commonly used probe drugs to assess function of intestinal P-glycoprotein (ABCB1) in humans. Handb Exp Pharmacol 2011:403-47.

Ota N, Hunt SC, Nakajima T et al. Linkage of interleukin 6 locus to human osteopenia by sibling pair analysis. Hum Genet 1999; 105:253-7.

Ota N, Nakajima T, Nakazawa I et al. A nucleotide variant in the promoter region of the interleukin-6 gene associated with decreased bone mineral density. J Hum Genet 2001; 46:267-72.

Ota S, Ishii G, Goto K et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 2009; 64:98-104.

Ota Y, Maruo Y, Matsui K, Mimura Y, Sato H, Takeuchi Y. Inhibitory effect of 5β-pregnane-3α,20β-Diol on transcriptional activity and enzyme activity of human bilirubin UDP-glucuronosyltransferase. Pediatr Res 2011; 70:453-7.

Otani K, Tybring G, Mihara K et al. Correlation between steady-state plasma concentrations of mianserin and trazodone in depressed patients. Eur J Clin Pharmacol 1998; 53:347-9.

Otani K, Ujike H, Sakai A et al. Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence. Neurosci Lett 2008; 434:88-92.

Otani M, Fukuda T, Naohara M et al. Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers. Eur J Clin Pharmacol 2003; 59:395-9.

Oterino A, Pascual J, Ruiz de Alegría C et al. Association of migraine and ESR1 G325C polymorphism. Neuroreport 2006; 17:61-4.

Oterino A, Valle N, Bravo Y et al. MTHFR T677 homozygosis influences the presence of aura in migraineurs. Cephalalgia 2004; 24:491-4.

Othman AA, Newman AH, Eddington ND. The novel N-substituted benztropine analog GA2-50 possesses pharmacokinetic and pharmacodynamic profiles favorable for a candidate substitute medication for cocaine abuse. J Pharm Sci 2008; 97:5453-70.

Othman AA, Syed SA, Newman AH, Eddington ND. Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Ther 2007; 320:344-53.

Otová B, Ojima I, Václavíková R et al. Second-generation taxanes effectively suppress subcutaneous rat lymphoma: role of disposition, transport, metabolism, in vitro potency and expression of angiogenesis genes. Invest New Drugs 2011. doi:10. 1007/s10637-011-9654-0.

Otsu K, Nishida K, Kimura Y et al. The point mutation Arg615→Cys in the Ca2+ release channel of skeletal sarcoplasmic reticulum is responsible for hypersensitivity to caffeine and halothane in malignant hyperthermia. J Biol Chem 1994; 269:9413-5.

Ott C, Schwarz T, Hilgers KF, Kreutz R, Schlaich MP, Schmieder RE. Left-ventricular structure and function are influenced by angiotensinogen gene polymorphism (-20 A/C) in young male patients. Am J Hypertens 2007; 20:974-80.

Ott M, Huls M, Cornelius MG, Fricker G. St. John’s Wort constituents modulate P-glycoprotein transport activity at the blood-brain barrier. Pharm Res 2010; 27:811-22.

Otto C, Lehrke M, Göke B. Novel insulin sensitizers: pharmacogenomic aspects. Pharmacogenomics 2002; 3:99-116.

Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996; 41:149-56.

Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993; 53:401-9.

Ou CY, Stevenson RE, Brown VK et al. 5,10 Methylenetetrahydrofolate reductase genetic polymorphism as a risk factor for neural tube defects. Am J Med Genet 1996; 63:610-4.

Oudard S, Legrier ME, Boyé K et al. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol 2003; 169:1729-34.

Ouellet D, Bramson C, Roman D et al. Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene. Br J Clin Pharmacol 2007; 63:59-66.

Ouellet D, Hsu A, Qian J et al. Effect of fluoxetine on pharmacokinetics of ritonavir. Antimicrob Agents Chemother 1998; 42:3107-12.

Ougolkov AV, Billadeau DD. Targeting GSK-3: a promising approach for cancer therapy? Future Oncol 2006; 2:91-100.

Ouma C, Davenport GC, Were T et al. Haplotypes of IL-10 promoter variants are associated with susceptibility to severe malarial anemia and functional changes in IL-10 production. Hum Genet 2008; 124:515-24.

Ourlin JC, Baader M, Fraser D, Halpert JR, Meyer UA. Cloning and functional expression of a first inducible avian cytochrome P450 of the CYP3A subfamily (CYP3A37). Arch Biochem Biophys 2000; 373:375-84.

Ourlin JC, Jounaïdi Y, Maurel P, Vilarem MJ. Role of the liver-enriched transcription factors C/EBP alpha and DBP in the expression of human CYP3A4 and CYP3A7. J Hepatol 1997; 26 Suppl 2:54-62.

Out C, Hageman J, Bloks VW et al. Liver receptor homolog-1 is critical for adequate up-regulation of Cyp7a1 gene transcription and bile salt synthesis during bile salt sequestration. Hepatology 2011; 53:2075-85.

Out R, Hoekstra M, Meurs I et al. Total body ABCG1 expression protects against early atherosclerotic lesion development in mice. Arterioscler Thromb Vasc Biol 2007; 27:594-9.

Ou-Yang DS, Huang SL, Wang Wet al. Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br J Clin Pharmacol 2000; 49:145-51.

Ovesen JL, Schnekenburger M, Puga A. Aryl hydrocarbon receptor ligands of widely different toxic equivalency factors induce similar histone marks in target gene chromatin. Toxicol Sci 2011; 121:123-31.

Ovsepian VA, Vinogradova EIu, Sherstneva ES. Cytochrome P4501A1, glutathione S-transferase M1 and T1 gene polymorphisms in chronic myeloid leukemia. Genetika 2010; 46:1360-2.

Ovsyannikova IG, Jacobson RM, Dhiman N, Vierkant RA, Pankratz VS, Poland GA. Human leukocyte antigen and cytokine receptor gene polymorphisms associated with heterogeneous immune responses to mumps viral vaccine. Pediatrics 2008; 121:1091-9.

Ovsyannikova IG, Jacobson RM, Ryan JE, Dhiman N, Vierkant RA, Poland GA. Relationship between HLA polymorphisms and gamma interferon and interleukin-10 cytokine production in healthy individuals after rubella vaccination. Clin Vaccine Immunol 2007; 14:115-22.

Ovsyannikova IG, Jacobson RM, Vierkant RA, Jacobsen SJ, Pankratz VS, Poland GA. Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination. J Infect Dis 2005; 191:515-9.

Ovsyannikova IG, Jacobson RM, Vierkant RA, Shane Pankratz V, Jacobsen SJ, Poland GA. Associations between human leukocyte antigen (HLA) alleles and very high levels of measles antibody following vaccination. Vaccine 2004; 22:1914-20.

Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. J Infect Dis 2006; 193:655-63.

Ovsyannikova IG, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA. Extended LTA, TNF, LST1 and HLA gene haplotypes and their association with rubella vaccine-induced immunity. PLoS One 2010. doi:10. 1371/journal. pone. 0011806.

Owen A, Chandler B, Back DJ, Khoo SH. Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. Antivir Ther 2004; 9:819-21.

Owen A, Khoo SH. Pharmacogenetics of antiretroviral agents. Curr Opin HIV AIDS 2008; 3:288-95.

Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK. Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol 2001; 51:345-9.

Owen F, Poulter M, Collinge J, Crow TJ. A codon 129 polymorphisms in the PRNP gene. Nucleic Acids Res 1990; 18:3103.

Owen F, Poulter M, Collinge J, Crow TJ. Codon 129 changes in the prion protein gene in Caucasians. Am J Hum Genet 1990; 46:1215-6.

Owen F, Poulter M, Lofthouse R et al. Insertion in prion protein gene in familial Creutfeldt-Jakob disease. Lancet 1989; 1:51-2.

Owen F, Poulter M, Shah T et al. An in-frame insertion in the prion protein gene in familial Creutfeldt-Jakob disease. Molec Brain Res 1990; 7:273-6.

Owen JR, Nemeroff CB. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depress Anxiety 1998; 7 Suppl 1:24-32.

Owen RT. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic. Drugs Today 2007; 43:249-58.

Owen RT. Agomelatine: a novel pharmacological approach to treating depression. Drugs Today 2009; 45:599-608.

Oyama T, Kim YD, Isse T et al. A pilot study on subacute ethanol treatment of ALDH2 KO mice. J Toxicol Sci 2007; 32:421-8.

Ozaki H, Ishikawa CT, Ishii T et al. Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis. J Clin Pharm Ther 2005; 30:189-92.

Ozawa S. Drug-drug interaction in pharmacogenetics and pharmacogenomics. Rinsho Byori 2002; 50:146-50.

Ozawa S, Ohta K, Miyajima A et al. Metabolic activation of o-phenylphenol to a major cytotoxic metabolite, phenylhydroquinone: role of human CYP1A2 and rat CYP2C11/CYP2E1. Xenobiotica 2000; 30:1005-17.

Ozawa S, Soyama A, Saeki M et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet 2004; 19:83-95.

Ozawa T, Brennan CW, Wang L et al. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev 2010; 24:2205-18.

Ozawa T, Ito M, Tamaki S et al. Gender and age effects on ventricular repolarization abnormality in Japanese general carriers of a G643S common single nucleotide polymorphism for the KCNQ1 gene. Circ J 2006; 70:645-50.

Ozbek YK, Oztürk T, Tüzüner BM et al. Combined effect of CYP1B1 codon 432 polymorphism and N-acetyltransferase 2 slow acetylator phenotypes in relation to breast cancer in the Turkish population. Anticancer Res 2010; 30:2885-9.

Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A. Interaction between grapefruit juice and diazepam in humans. Eur J Drug Metab Pharmacokinet 1998; 23:55-9.

Ozdemir V, Bertilsson L, Miura J et al. CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited. Pharmacogenet Genomics 2007; 17:339-47.

Ozdemir V, Fourie J, Busto U, Naranjo CA. Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence? Clin Pharmacokinet 1996; 31:372-85.

Ozdemir V, Kalow W, Tang BK et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000; 10:373-88.

Ozdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W. Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther 1997; 62:334-47.

Ozdemir V, Naranjo CA, Shulman RW et al. Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. J Clin Psychopharmacol 1998; 18:198-207.

Ozeki J, Uno S, Ogura M et al. Aryl hydrocarbon receptor ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin enhances liver damage in bile duct-ligated mice. Toxicology 2011; 280:10-7.

Ozhan G, Yanar TH, Ertekin C, Alpertunga B. The effect of genetic polymorphisms of cyclooxygenase 2 on acute pancreatitis in Turkey. Pancreas 2010; 39:371-6.

Ozkaya O, Söylemezoğlu O, Gönen S et al. Renin-angiotensin system gene polymorphisms: association with susceptibility to Henoch-Schonlein purpura and renal involvement. Clin Rheumatol 2006; 25:861-5.

Ozsvár Z, Solymossi Z, Monostory K. Methyldopa-induced acute reactive hepatitis in pregnancy, drug-metabolizing capacity of the liver. Orv Hetil 2010; 151:457-61.

Oztekin S, Mavioglu O, Elar Z, Guven H, Kalkan S, Gurpinar T. The effects of gender and menopause on serum lidocaine levels in smokers. Eur J Drug Metab Pharmacokinet 2005; 30:231-4.

Ozturk A, Desai PP, Minster RL, Dekosky ST, Kamboh MI. Three SNPs in the GSTO1, GSTO2 and PRSS11 genes on chromosome 10 are not associated with age-at-onset of Alzheimer’s disease. Neurobiol Aging 2005; 26:1161-5.

Oztürk T, Kahraman OT, Toptas B et al. The effect of CYP1A1 and GSTM1 gene polymorphisms in bladder cancer development in a Turkish population. In Vivo 2011; 25:663-8.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z